Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m. Marinus is a commercial-stage pharmaceutical company ...

Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and Exchange Commission.

The company’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.73. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $9.24. The firm has a market ...

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Tuesday ...

MARINUS PHARMACEUTICALS ($MRNS) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting ...

Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and ...